Boston Scientific Shares At New Session High, Up 3%, As Co.’s Investor Day Currently Ongoing
https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/documents/events/BSX-Investor-Day-2021-22Sep-final-final.pdf
Boston Scientific Acquires Provider Of Thrombectomy Platform In Over $300M Deal
Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Devoro Medical Inc for over 300 million. Boston Scientific has been a strategic investor…
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
Boston Scientific Posts Colorectal Cancer Survival Data For Tumor-Targeting Microbeads
Boston Scientific Corporation (NYSE:BSX) announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres (TheraSphere treatment) met both…
‘Fast Money Halftime Report’ Picks For September 15
On CNBC's "Fast Money Halftime Report," Karen Firestone said Charles Schwab (NYSE: SCHW) has a lot of new young traders who have larger accounts than Robinhood Mar
Abbott Says Amulet Superior To Boston Scientific’s Watchman In Stroke Study
Abbott Laboratories (NYSE:ABT) has announced late-breaking data from the Amulet LAA Occluder IDE trial. The head-to-head study compared Abbott’s Amplatzer Amulet…
Where Boston Scientific Stands With Analysts
Within the last quarter, Boston Scientific (NYSE:BSX) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
Post Market Studies Reinforce Unfavorable Risk-Benefit Profile For Boston Scientific’s Vaginal Mesh
Final results from postmarket surveillance studies of Boston Scientific Corporation's (NYSE: BSX) transvaginal mesh for pelvic organ prolapse (POP) have reinforced the FDA's unfavorable view of the benefit-risk profile.
Miromatrix Medical Reports Strategic Investors Were Involved In Series C Financing Following IPO: Baxter, CareDx, DaVita; No Size Of Investment Disclosed
Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save patients' lives and improve quality of life around the world,
Boston Scientific’s Exalt Model B Single-Use Bronchoscope Wins FDA Approval
The FDA has given 510(k) clearance for Boston Scientific Corp’s (NYSE:BSX) Exalt Model B single-use bronchoscope for use in bedside…